Market Cap 139.52B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 7.90
Forward PE 8.17
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 44,130,320
Avg Vol 41,914,176
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 57%
Beta 0.35
Analysts Sell
Price Target $28.80

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
WuTangClam
WuTangClam Jul. 15 at 9:39 PM
$PFE feeling good about my pick up at 24.10c .. I was really wanting to pick up shares in the 23$ range. Also holding leaps 25.50 strike exp Sept
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 8:37 PM
Merck shares gained after the company announced that its Phase 3 KEYNOTE-C93 trial met its primary endpoint of progression-free survival, demonstrating that Keytruda monotherapy outperformed standard chemotherapy in patients with advanced or recurrent mismatch repair-deficient endometrial cancer. The study also showed a favorable trend in overall survival at a prespecified interim analysis, further strengthening Keytruda's clinical profile. In a separate Phase 3 study, Kelun-Biotech's TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan, combined with Keytruda, met its primary endpoint of progression-free survival in PD-L1-negative non-small cell lung cancer patients. The trial marks the first global Phase 3 success in this difficult-to-treat population and reinforces Keytruda's role as a key combination therapy across multiple cancer indications. $MRK $PFE $LLY
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 15 at 8:21 PM
$PFE When is the last time we had an up day with no huge sell-off? Has to be like 4 long months ago at least
1 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 15 at 8:08 PM
$PFE very odd
1 · Reply
BB_88_
BB_88_ Jul. 15 at 8:00 PM
$PFE finally no selloff
0 · Reply
Bomber18
Bomber18 Jul. 15 at 7:49 PM
$SLS $PFE you know who to call to make up for this debacle. Time to put your best foot forward and consummate the deal. https://www.biospace.com/drug-development/pfizer-scraps-seagen-developed-adc-for-solid-tumors
0 · Reply
jrh34
jrh34 Jul. 15 at 7:41 PM
$CRDF I said that, go look at how low $SLS traded. down into the .50 range, all along there was insider buying. Now they are over $13. When a stock dips this low and insiders scatter that's when you worry. But here with $CRDF we have multiple insiders buying over $1M worth of shares at $1.43 - they paid a premium. If that doesn't telegraph what they know behind the scenes I don't know what does. I was able to buy cheaper than insiders today and cheaper than the direct investor (which I'm thinking was $PFE) who paid $1.05 for $9 million worth of shares. That's a win in my book.
1 · Reply
Warrent_jr
Warrent_jr Jul. 15 at 7:17 PM
$INDO BULLISH $12.. Bro follows Warrent_jr more closely than he follows his own $PFE position ???..what the fuck !!! If my INDO posts hurt you this much, there’s always a mute button. Focus on getting PFE back to $26 first....bloody idiot..!!
1 · Reply
ultraviolin
ultraviolin Jul. 15 at 7:09 PM
$PFE Please , go back to 26. It's a painfully slow crawl you have ....
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 15 at 6:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
Latest News on PFE
Pfizer price target lowered to $30 from $34 at BMO Capital

2026-07-13T12:26:33.000Z - 2 days ago

Pfizer price target lowered to $30 from $34 at BMO Capital


Pfizer price target lowered to $35 from $36 at Guggenheim

2026-07-13T11:06:16.000Z - 2 days ago

Pfizer price target lowered to $35 from $36 at Guggenheim


Pfizer price target lowered to $26 from $27 at BofA

2026-07-10T10:30:21.000Z - 5 days ago

Pfizer price target lowered to $26 from $27 at BofA


Pfizer price target lowered to $28 from $30 at JPMorgan

2026-07-08T12:15:37.000Z - 7 days ago

Pfizer price target lowered to $28 from $30 at JPMorgan


Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade

2026-07-07T15:54:25.000Z - 8 days ago

Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 9 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer downgraded to Hold from Buy at HSBC

2026-07-06T09:50:29.000Z - 9 days ago

Pfizer downgraded to Hold from Buy at HSBC


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 21 days ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 21 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 27 days ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 27 days ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 5 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 5 weeks ago

Pfizer Press release: Study update


Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 6 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA


Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 2 months ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC


Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 2 months ago

Pfizer CEO on AI-designed molecule, and race to use new tech


3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 2 months ago

3 Dividend Stocks for May 2026

SYY WSO


Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings Call Transcript: Q1 2026


Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings release: Q1 2026


Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Quarterly report: Q1 2026


Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Slides: Q1 2026


Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 2 months ago

Pfizer Posts Better-Than-Expected Revenue, Profit


Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:23 AM EDT - 2 months ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending


Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 2 months ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS


WuTangClam
WuTangClam Jul. 15 at 9:39 PM
$PFE feeling good about my pick up at 24.10c .. I was really wanting to pick up shares in the 23$ range. Also holding leaps 25.50 strike exp Sept
0 · Reply
topstockalerts
topstockalerts Jul. 15 at 8:37 PM
Merck shares gained after the company announced that its Phase 3 KEYNOTE-C93 trial met its primary endpoint of progression-free survival, demonstrating that Keytruda monotherapy outperformed standard chemotherapy in patients with advanced or recurrent mismatch repair-deficient endometrial cancer. The study also showed a favorable trend in overall survival at a prespecified interim analysis, further strengthening Keytruda's clinical profile. In a separate Phase 3 study, Kelun-Biotech's TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan, combined with Keytruda, met its primary endpoint of progression-free survival in PD-L1-negative non-small cell lung cancer patients. The trial marks the first global Phase 3 success in this difficult-to-treat population and reinforces Keytruda's role as a key combination therapy across multiple cancer indications. $MRK $PFE $LLY
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 15 at 8:21 PM
$PFE When is the last time we had an up day with no huge sell-off? Has to be like 4 long months ago at least
1 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 15 at 8:08 PM
$PFE very odd
1 · Reply
BB_88_
BB_88_ Jul. 15 at 8:00 PM
$PFE finally no selloff
0 · Reply
Bomber18
Bomber18 Jul. 15 at 7:49 PM
$SLS $PFE you know who to call to make up for this debacle. Time to put your best foot forward and consummate the deal. https://www.biospace.com/drug-development/pfizer-scraps-seagen-developed-adc-for-solid-tumors
0 · Reply
jrh34
jrh34 Jul. 15 at 7:41 PM
$CRDF I said that, go look at how low $SLS traded. down into the .50 range, all along there was insider buying. Now they are over $13. When a stock dips this low and insiders scatter that's when you worry. But here with $CRDF we have multiple insiders buying over $1M worth of shares at $1.43 - they paid a premium. If that doesn't telegraph what they know behind the scenes I don't know what does. I was able to buy cheaper than insiders today and cheaper than the direct investor (which I'm thinking was $PFE) who paid $1.05 for $9 million worth of shares. That's a win in my book.
1 · Reply
Warrent_jr
Warrent_jr Jul. 15 at 7:17 PM
$INDO BULLISH $12.. Bro follows Warrent_jr more closely than he follows his own $PFE position ???..what the fuck !!! If my INDO posts hurt you this much, there’s always a mute button. Focus on getting PFE back to $26 first....bloody idiot..!!
1 · Reply
ultraviolin
ultraviolin Jul. 15 at 7:09 PM
$PFE Please , go back to 26. It's a painfully slow crawl you have ....
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jul. 15 at 6:51 PM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
Jack90
Jack90 Jul. 15 at 6:47 PM
Loading $PFE, $BMY, $JNJ
0 · Reply
JPOWEEZY
JPOWEEZY Jul. 15 at 6:47 PM
$PFE Time to pump it
0 · Reply
JBS_84
JBS_84 Jul. 15 at 6:19 PM
$PFE Still think this. Might get a bit of a drop today but it will get bought rapidly.
1 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:30 PM
$DJT $ELTP $PFE $BAC $GME With the help of Jesus SequestOx will be approved and Save the World. Thank you SequestOx is an investigational, abuse-deterrent immediate-release oxycodone and naltrexone capsule developed by Elite Pharmaceuticals for the management of moderate-to-severe pain. It utilizes sequestered antagonist technology to block the euphoric effects of the opioid if the medication is crushed, dissolved, or manipulated for misuse.
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 15 at 5:04 PM
$DJT $JNJ $PFE $MRNA $LLY Let me share a little secret with you..... This is why ELTP is going to be Big..... Their Technology will save the world... Look it up/ Here are the two people who are backing ELTP.
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 15 at 4:36 PM
$OTLK 2 weeks before 7/29/26 #PDUFA… Bottom Bollinger looks like 1.40? How many more more super sales, can it drop under 1.40, with a little help from some stop losses, or shorts? #stillLONG $REGN $PFE $JNJ
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 15 at 3:37 PM
$PFE What is this bluish yellow color? What is happening? Doesn't the market know its almost noon?
2 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Jul. 15 at 3:17 PM
$PFE pushed above the Point of Control on the Daily Chart in addition to being above last 3-weeks action and the 20dma. Gap fill target around 25.9x area that would be above 50dma and also the 200dma base area for a much more bullish disposition from there. Easy peezy....
0 · Reply
Oiljunkie
Oiljunkie Jul. 15 at 3:13 PM
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 15 at 2:45 PM
$PFE Its doing the thing that Lilly does. Weird
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jul. 15 at 2:39 PM
Green $PFE? Sus. As usual.
1 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 15 at 2:36 PM
$PFE I say again, why can’t you just be normal
0 · Reply